使用变性高效液相色谱法分析结直肠癌患者粪便DNA中的微卫星不稳定性。
Analysis of microsatellite instability in stool DNA of patients with colorectal cancer using denaturing high performance liquid chromatography.
作者信息
Lim Seok-Byung, Jeong Seung-Yong, Kim Il-Jin, Kim Dae Yong, Jung Kyung Hae, Chang Hee Jin, Choi Hyo Seong, Sohn Dae Kyung, Kang Hio Chung, Shin Yong, Jang Sang-Geun, Park Jae-Hyun, Park Jae-Gahb
机构信息
Research Institute and Hospital, National Cancer Center, Goyang, and Cancer Research Institute and Cancer Research Center, Seoul National University, Seoul, Korea.
出版信息
World J Gastroenterol. 2006 Nov 7;12(41):6689-92. doi: 10.3748/wjg.v12.i41.6689.
AIM
To evaluate the usefulness of denaturing high performance liquid chromatography (DHPLC) for analyzing microsatellite instability (MSI) status in stool DNA of patients with colorectal cancer.
METHODS
A total of 80 cancer tissues from patients with primary sporadic colorectal tumor (proximal cancer: 27, distal cancer: 53) and matched stool (which were employed for comparison with the tissues) were analyzed for MSI status in BAT 26. DNA samples extracted from stool were evaluated by nested polymerase chain reaction (PCR) and DHPLC for MSI analysis.
RESULTS
Six cases (7.5%) of MSI were identified in BAT 26 from 80 cancer tissues. All the stool DNA samples from patients whose cancer tissue showed MSI also displayed MSI in BAT 26.
CONCLUSION
As MSI is one of the established fecal DNA markers to screen colorectal cancer, we propose to use DHPLC for the MSI analysis in fecal DNA.
目的
评估变性高效液相色谱法（DHPLC）分析结直肠癌患者粪便DNA中微卫星不稳定性（MSI）状态的实用性。
方法
对80例原发性散发性结直肠肿瘤患者的癌组织（近端癌：27例，远端癌：53例）及配对粪便（用于与组织进行比较）进行BAT26基因座的MSI状态分析。采用巢式聚合酶链反应（PCR）和DHPLC对粪便提取的DNA样本进行MSI分析。
结果
80例癌组织的BAT26基因座中，6例（7.5%）检测到MSI。癌组织显示MSI的患者的所有粪便DNA样本在BAT26基因座也显示MSI。
结论
由于MSI是已确立的用于筛查结直肠癌的粪便DNA标志物之一，我们建议使用DHPLC进行粪便DNA的MSI分析。
Zotero 插件